PhaseV's AI Platforms Adopted by Seven Pharma Giants for Clinical Trial Optimization
核心洞察
PhaseV (搜索)'s machine learning platforms are now utilized by seven global pharmaceutical companies to enhance drug development processes.
The AdaptV Platform optimizes adaptive trial design, while the Causal Platform identifies hidden signals in clinical data for precision medicine.
These platforms guide indication selection and expansion across therapeutic areas like oncology (搜索), immunology (搜索), and CNS (搜索) disorders.
PhaseV (搜索), a company specializing in machine learning (ML) for clinical trial optimization, announced that seven global pharmaceutical companies are now using its ML platforms for drug development. This adoption, within two years of PhaseV's market entry, signifies a shift towards data-driven approaches in the pharmaceutical industry.
AI Platforms in Action
Pharma companies are leveraging PhaseV (搜索)'s AdaptV Platform to optimize adaptive trial design and execution. The Causal Platform is also being utilized to uncover hidden signals in clinical data, facilitating more precise drug development. These platforms support indication selection and expansion across multiple therapeutic areas, including oncology (搜索), immunology (搜索), CNS (搜索), and respiratory disorders (搜索).
Driving Efficiency and Precision
Raviv Pryluk, PhD, CEO and Co-founder of PhaseV (搜索), stated, "We are proud to see some of the world's leading pharma companies embracing our technology to de-risk their clinical development, accelerate the time to market of potentially life-saving drugs, and make sure they reach the right patients." He emphasized the growing trust in AI for smarter, faster, and more effective drug development.
Platform Capabilities
The AdaptV Platform uses proprietary algorithms to optimize the design of adaptive trials, enabling sponsors to design more efficient and successful trials, adjust in real-time to emerging data, and better align with regulatory expectations. The Causal Platform uses causal machine learning to detect subtle, hidden patterns within clinical and real-world data, enabling more accurate decision-making and better identification of promising endpoints or subpopulations for treatments in development.
Industry Perspective
Dr. David Perry, Chief Medical Officer at Orasee Bioscience and Principal at Lilium Bioscience, noted, "The shift toward AI-driven solutions in drug development is evident and exciting, as biotech and pharma companies seek better efficiency and more predictable results from their clinical trials." He added that AI would become an integral part of the drug development ecosystem, helping developers unlock new possibilities and bring new therapies to patients faster and with greater medical precision.